(Q35599599)

9 August 2017

0 references

1 reference

title

Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients (English)

1 reference

9 August 2017

0 references

1 reference

1 reference

1 reference

1 reference

Fabrizi F

1

1 reference

9 August 2017

Dulai G

2

1 reference

9 August 2017

Dixit V

3

1 reference

9 August 2017

Bunnapradist S

4

1 reference

9 August 2017

Martin P

5

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

Alimentary Pharmacology & Therapeutics

9 August 2017

published in

1 reference

9 August 2017

volume

18

1 reference

9 August 2017

issue

11-12

1 reference

9 August 2017

page(s)

1071-1081

1 reference

Hepatitis C virus infection in French hemodialysis units: a multicenter study

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

National surveillance of dialysis-associated diseases in the United States, 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Impact of dialysis room and reuse strategies on the incidence of hepatitis C virus infection in haemodialysis units

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Hepatitis virus infection in haemodialysis patients from Moldavia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Cancer in patients on dialysis for end-stage renal disease: an international collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Impact of hepatitis B and C virus on kidney transplantation outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Impaired kidney transplant survival in patients with antibodies to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Association of hepatitis C virus infection with mortality and graft survival in kidney-pancreas transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Effectiveness and tolerance of interferon-alpha 2b in the treatment of chronic hepatitis C in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Interferon treatment for hepatitis C virus infection in patients on haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Introduction to therapy of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Hepatitis C infection and the patient with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Changes in viremia and circulating interferon-alpha during hemodialysis in hepatitis C virus-positive patients: only coincidental phenomena?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

The tolerance and efficacy of interferon‐α in haemodialysis patients with HCV infection: a multicentre, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01780.X

10.1046/J.1365-2036.2003.01780.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference